Added Value of Gadoxetic Acid-enhanced Liver MRI

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

130 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-12-29

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It would be valuable to evaluate whether gadoxetic acid-enhanced liver MRI would provide additional value for characterizing atypical or small (1\~2cm) hepatic nodules at CT and to reduce the necessity of biopsy in patients with high risk of HCC.

Therefore, the purpose of this study is to evaluate added value of gadoxetic acid-enhanced MRI for diagnosis of HCC in patients with small (10-19mm) or atypical hepatic nodules at CT.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Gadoxetic Acid-enhanced MR Evaluation of Hepatocellular Carcinoma and Dysplastic Nodules in the Cirrhotic Liver

NCT01501240

Liver Cirrhosis Carcinoma, Hepatocellular

WITHDRAWN

Abbreviated MRI Using Gadoxetic Acid Versus CT for Surveillance of Recurrent HCC After Curative Treatment

NCT06537193

Hepatocellular Carcinoma

RECRUITING NA

Abbreviated MRI for HCC Surveillance

NCT03731923

Hepatocellular Carcinoma Liver Cirrhosis Chronic Hepatitis

UNKNOWN NA

Short-term MRI for Treatment Response Evaluation/Prediction of HCC Treated With TARE

NCT03731910

Hepatocellular Carcinoma

UNKNOWN NA

Abbreviated MRI Using Gadoxetic Acid Versus Ultrasonography for Surveillance of Early-stage HCC in Patients at High Risk

NCT06312826

Liver Cirrhosis Hepatocellular Carcinoma

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In terms of confirmative diagnosis, HCC is unique compared with other malignant tumors, as it can be diagnosed noninvasively based on its characteristic imaging features, that is, arterial hyperenhancement (washin) and hypoenhancement (washout) on portal or delayed phase at contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) using extracellular contrast media (ECCM). According to Liver Imaging Reporting and Data System (LI-RADS), hypointensity and isointensity on hepatobiliary phase (HBP) at gadoxetic acid-enhanced MRI are suggestive of malignancy and benignity, respectively, and those features are uniquely provided by only hepatocyte-specific contrast agent. However, these features are not included in diagnostic criteria because of its non-specificity, and indeed, gadoxetic acid-enhanced MRI is not yet included in AASLD and EASL guidelines as a diagnostic modality. If gadoxetic acid-enhanced MRI would provide better performance to diagnose HCC than CT, gadoxetic acid-enhanced MRI should be considered as a next step before biopsy in those small and/or atypical nodules to avoid potential diagnostic pitfall and morbidity, which is currently depending on physicians' decision. Thus, it would be valuable to evaluate whether gadoxetic acid-enhanced liver MRI would provide additional value for characterizing atypical or small (1\~2cm) hepatic nodules at CT and to reduce the necessity of biopsy in patients with high risk of HCC.

Therefore, the purpose of this study is to evaluate added value of gadoxetic acid-enhanced MRI for diagnosis of HCC in patients with small (10-19mm) or atypical hepatic nodules at CT.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hcc Diagnosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients group

* with small hepatic nodules (10-19mm) or atypical hepatic nodule (= or \> 20mm) and high-risk group of HCC
* scheduled for gadoxetic acid-enhanced liver MRI or liver nodule biopsy

gadoxetic acid-enhanced liver MRI

Intervention Type PROCEDURE

liver MRI using a standard dose (0.025mmol/kg) of gadoxetic acid

Living liver donor candidates

* living liver donor candidates without history of liver disease
* schedule for gadoxetic acid-enhanced liver MRI as preoperative workup
* only used for control of normal liver parenchymal enhancement on hepatobiliary phase

gadoxetic acid-enhanced liver MRI

Intervention Type PROCEDURE

liver MRI using a standard dose (0.025mmol/kg) of gadoxetic acid

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

gadoxetic acid-enhanced liver MRI

liver MRI using a standard dose (0.025mmol/kg) of gadoxetic acid

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with chronic hepatitis B or cirrhosis of any etiology
* signed informed consent AND
* being referred to radiology department for gadoxetic acid-enhanced MRI due to small nodule (10-19mm) at contrast-enhanced CT scan within 30 days as an radiofrequency ablation (RFA) work-up OR
* being referred to radiology department for percutaneous biopsy for atypical hepatic nodules (≥20mm) detected at contrast-enhanced CT within 30 days before biopsy